Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DEFIBROTIDE Cause Venoocclusive liver disease? 355 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 355 reports of Venoocclusive liver disease have been filed in association with DEFIBROTIDE (DEFITELIO). This represents 9.5% of all adverse event reports for DEFIBROTIDE.

355
Reports of Venoocclusive liver disease with DEFIBROTIDE
9.5%
of all DEFIBROTIDE reports
272
Deaths
73
Hospitalizations

How Dangerous Is Venoocclusive liver disease From DEFIBROTIDE?

Of the 355 reports, 272 (76.6%) resulted in death, 73 (20.6%) required hospitalization, and 61 (17.2%) were considered life-threatening.

Is Venoocclusive liver disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DEFIBROTIDE. However, 355 reports have been filed with the FAERS database.

What Other Side Effects Does DEFIBROTIDE Cause?

Off label use (1,323) Venoocclusive disease (576) Death (463) Multiple organ dysfunction syndrome (372) Intentional product use issue (201) Hypotension (169) Haemorrhage (156) Sepsis (143) Acute graft versus host disease (140) Gastrointestinal haemorrhage (125)

What Other Drugs Cause Venoocclusive liver disease?

CYCLOPHOSPHAMIDE (911) BUSULFAN (765) FLUDARABINE (649) VINCRISTINE (616) METHOTREXATE (590) CYTARABINE (573) ETOPOSIDE (523) OXALIPLATIN (521) MELPHALAN (464) DEXAMETHASONE (371)

Which DEFIBROTIDE Alternatives Have Lower Venoocclusive liver disease Risk?

DEFIBROTIDE vs DEFLAZACORT DEFIBROTIDE vs DEGARELIX DEFIBROTIDE vs DELAFLOXACIN MEGLUMINE DEFIBROTIDE vs DELAMANID DEFIBROTIDE vs DELANDISTROGENE MOXEPARVOVEC-ROKL

Related Pages

DEFIBROTIDE Full Profile All Venoocclusive liver disease Reports All Drugs Causing Venoocclusive liver disease DEFIBROTIDE Demographics